List of Selzentry drug patents
Selzentry is owned by Viiv Hlthcare.
Selzentry contains Maraviroc.
Selzentry has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Selzentry are:
- US6667314*PED
- US7368460
- US7368460*PED
Selzentry was authorised for market use on 04 November, 2016.
Selzentry is available in solution;oral dosage forms.
Selzentry can be used as method of treating patients infected with ccr5-tropic hiv-1.
The generics of Selzentry are possible to be released after 30 April, 2024.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6667314 (Pediatric) | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Feb, 2022
(1 year, 3 months ago) | |
| US7368460 | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Nov, 2022
(6 months ago) | |
|
US7368460 (Pediatric) | VIIV HLTHCARE | Tropane derivatives useful in therapy |
May, 2023
(12 days ago) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Oct 30, 2023 |
| Pediatric Exclusivity (PED) | Apr 30, 2024 |
Drugs and Companies using MARAVIROC ingredient
Market Authorisation Date: 04 November, 2016
Treatment: Method of treating patients infected with ccr5-tropic hiv-1
Dosage: SOLUTION;ORAL
SELZENTRY family patents
5
United States
3
Spain
3
Malaysia
3
Norway
3
Hong Kong
3
Germany
3
China
3
European Union
2
Australia
2
EA
2
Korea, Republic of
2
Denmark
2
Austria
2
Portugal
2
Japan
2
United Kingdom
2
Slovenia
2
Argentina
1
Panama
1
Ecuador
1
AP
1
Iceland
1
Luxembourg
1
Israel
1
Egypt
1
Croatia
1
IB
1
OA
1
Netherlands
1
Canada
1
Yugoslavia
1
New Zealand
1
Tunisia
1
Uruguay
1
Peru
1
Costa Rica
1
Slovakia
1
Cyprus
1
Algeria
1
Estonia
1
ME
1
Bulgaria
1
Czech Republic
1
Ukraine
1
Poland
1
Morocco
1
Georgia
1
RS
1
Brazil
1
Cuba
1
South Africa
1
Guatemala
1
Mexico
1
Hungary
1
Turkey
1
Taiwan
1
Lithuania
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic